X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Rectiv-Generic (nitroglycerin) is a nitrate vasodilator which activates guanylate cyclase, resulting in an increase of cyclic GMP in smooth muscle and other tissues. It is indicated for the treatment of moderate to severe pain associated with chronic anal fissure.
Lead Product(s): Nitroglycerin
Therapeutic Area: Gastroenterology Product Name: Rectiv-Generic
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 22, 2024
Details:
Through the divestment, Cosette will further expand its women's health platform by adding Vyleesi (bremelanotide acetate), the first and only as-needed treatment approved for premenopausal women with acquired, generalized hypoactive sexual desire disorder.
Lead Product(s): Bremelanotide Acetate
Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: Vyleesi
Highest Development Status: ApprovedProduct Type: Peptide
Recipient: Palatin Technologies
Deal Size: $171.0 million Upfront Cash: $12.0 million
Deal Type: Acquisition January 03, 2024
Details:
Through the divestment, Cosette will further expand its women's health platform by adding Vyleesi (bremelanotide acetate), the first and only as-needed treatment approved for premenopausal women with acquired, generalized hypoactive sexual desire disorder.
Lead Product(s): Bremelanotide Acetate
Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: Vyleesi
Highest Development Status: ApprovedProduct Type: Peptide
Recipient: Palatin Technologies
Deal Size: $171.0 million Upfront Cash: $12.0 million
Deal Type: Divestment January 02, 2024
Details:
Through the divestment, Cosette will further expand its women's health platform by adding Vyleesi (bremelanotide acetate), the first and only as-needed treatment approved for premenopausal women with acquired, generalized hypoactive sexual desire disorder.
Lead Product(s): Bremelanotide Acetate
Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: Vyleesi
Highest Development Status: ApprovedProduct Type: Peptide
Recipient: Palatin Technologies
Deal Size: $171.0 million Upfront Cash: $12.0 million
Deal Type: Divestment December 20, 2023
Details:
Dapsone (metronidazole) is a vaginal gel, generic version of MetroGel-Vaginal by Bausch Health, and is indicated for the topical treatment of inflammatory lesions of rosacea.
Lead Product(s): Metronidazole
Therapeutic Area: Infections and Infectious Diseases Product Name: Dapsone
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 27, 2023
Details:
Aczone contains dapsone, a sulfone, in an aqueous gel base indicated for the topical treatment of acne vulgaris. It works by killing or preventing the growth of bacteria on the skin.
Lead Product(s): Dapsone
Therapeutic Area: Dermatology Product Name: Aczone-Generic
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: SeegPharm
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 13, 2023
Details:
The acquisition accelerates Cosette’s women’s health portfolio, with a differentiated, commercial stage, patent protected product, Intrarosa (prasterone), the only prescription drug providing both estrogen and androgen for the treatment of moderate-to-severe dyspareunia.
Lead Product(s): Prasterone
Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: Intrarosa
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Endoceutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition June 08, 2023
Details:
Cystadane (betaine anhydrous) transfers a methyl group via the enzyme betaine homocysteine methyl transferase, converting homocysteine back into methionine and dimethylglycine. In patients with homocystinuria, betaine reduces homocysteine levels and improves health outcomes.
Lead Product(s): Betaine
Therapeutic Area: Genetic Disease Product Name: Cystadane
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 02, 2023
Details:
Metronidazole diffuses into the organism, inhibits protein synthesis by interacting with DNA, and causes a loss of helical DNA structure and strand breakage. Therefore, it causes cell death in susceptible organisms.
Lead Product(s): Metronidazole
Therapeutic Area: Infections and Infectious Diseases Product Name: Metronidazole-Generic
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 09, 2023
Details:
Griseofulvin microsize contains griseofulvin microsize for oral administration. The active ingredient, griseofulvin, is a fungistatic antibiotic, derived from a species of Penicillium.
Lead Product(s): Griseofulvin
Therapeutic Area: Infections and Infectious Diseases Product Name: Griseofulvin-Generic
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 06, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
